ClinicalTrials.gg
CompletedNCT04833270Updated Sep 27, 2022

Pragmatic Randomized Controlled Trial of Non-pharmacological Treatment for Lumbar Disc Herniation : A Pilot Study

An interventional study of KM non-pharmacological treatment group and Pharmacological treatment group in Lumbar Disc Prolapse With Radiculopathy, sponsored by Jaseng Hospital of Korean Medicine. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-09-27.

Sponsored by Jaseng Hospital of Korean Medicine · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
19 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Radiculopathy with a site in Korea, Republic of — 2 open to participants now, 5 under way, none of them phase 3. Radiculopathy · Korea, Republic of.

Enrollment
10th of 11
30 · median 70
Started
2021
the only one that year
No phase
10 of 16
1 open now
Registered
8th of 16
by date
Lead sponsor
1 of 16
Jaseng Hospital of Korean Medicine

Among the 16 studies in Radiculopathy with a site in Korea, Republic of, this one is the 10th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2021, is one of 10 with no phase, and was the 8th registered.

Radiculopathy

488 studies on the registry are indexed under Radiculopathy; 145 are open to participants now.

Browse Radiculopathy studies →

Open to participants now

2 of the 16 studies in Radiculopathy with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 79 Radiculopathy studies recruiting now, 23 (29%) set no upper age limit and 48 (61%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.

This study: 19 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Radiculopathy with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This is a 2-arm parallel pragmatic randomized controlled trial that will compare non-pharmacological treatment with pharmacological therapy for lumbar disc herniation.

Read the detailed description

Participants who voluntarily signed informed consent form and eligible for the study were randomly assigned in a 1:1 ratio (15:15) for non-pharmacological treatment and pharmacological treatment group. Participants of each group will receive twice a week for total 8 weeks of intervention. This is a pragmatic randomized controlled trial, so physicians will have medical decision making according to each participant's conditions and choose the specific intervention and dosage of pharmacological and non-pharmacological treatment.

03

Conditions studied

  • Lumbar Disc Prolapse With Radiculopathy

Browse trials for

04

Who can participate

Ages eligible
19 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Numeric rating scale (NRS) score of radiating pain 5 or more for recent 3 serial days.
  2. Onset time of radiating pain occurred within 12 weeks.
  3. Radiologically diagnosed with lumbar disc herniation in lumbar spine magnetic resonance imaging (L-spine MRI)
  4. 19-70 years old
  5. participants who agreed and signed form

Exclusion criteria

Exclusion Criteria:

  1. Spine of cancer, acute fracture of spine, or spine dislocation
  2. Progressive neurologic deficits or severe neurologic deficits
  3. Soft tissue diseases that can induce low back pain(ie. cancer, fibromyalgia, rheumatoid arthritis, gout,etc)
  4. Presence of chronic underlying disease which can interfere the efficacy or interpretation (ie. stroke, myocardial infarct, kidney disease, dementia, diabetic neuropathy, epilepsy, etc)
  5. Concurrent use of , , orpsychotropic medications or any other medication that can interrupt the study result
  6. Hemorrhagic disease, severe diabetes or taking anticoagulant drug
  7. Participants who took NSAIDs or pharmacopuncture within 1 week
  8. Pregnant or lactating women
  9. Participants who had undergone lumbar surgery within 3 months
  10. Participants who had participated in other clinical trial within 1 month, or have plan for participation in other trial during follow up period of this trial
  11. Participants who can not write
  12. Participants who is difficult to participate in the trial according to investigator's decision
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    KM non-pharmacological treatment group

    Non-pharmacological treatment including Korean medicine will be implemented to the participants twice a week for total 8 weeks. The specific intervention will be determined according to the physician's choice, and information will be recorded in the case report form.

    Other: KM non-pharmacological treatment group

  • Active comparator
    Pharmacological treatment group

    Pharmacological treatment will be implemented to the participants twice a week for total 8 weeks. The specific intervention will be determined according to the physician's choice, and information will be recorded in the case report form.

    Other: Pharmacological treatment group

Interventions

  • OtherKM non-pharmacological treatment group

    This is a pragmatic setting, and specific intervention is not determined prior to the study. Non-pharmacological treatment including Korean medicine, such as acupuncture, electroacupuncture and chuna, etc, will be chosen by professional physician according to the medical condition of each subject.

  • OtherPharmacological treatment group

    This is a pragmatic setting, and specific intervention is not determined prior to the study. The pharmacological treatment will be chosen by professional physician according to the medical condition of each subject.

06

What researchers measure

Primary outcomes

  1. Numeric rating scale (NRS) of radiating pain in lower extremities

    NRS is a pain scale in which the patient indicates their subjective pain as awhole number from 0 to 10, where 0 indicates 'no pain or discomfort' and10 indicates 'the most severe pain and discomfort imaginable'.

    Time frame: week 9

Secondary outcomes

  1. Numeric rating scale (NRS) of radiating pain in lower extremities

    NRS is a pain scale in which the patient indicates their subjective pain as awhole number from 0 to 10, where 0 indicates 'no pain or discomfort' and10 indicates 'the most severe pain and discomfort imaginable'.

    Time frame: week 1, 2, 3, 4, 5, 6, 7, 8, 9, 14, 27

  2. Numeric rating scale (NRS) of low-back pain

    NRS is a pain scale in which the patient indicates their subjective pain as awhole number from 0 to 10, where 0 indicates 'no pain or discomfort' and10 indicates 'the most severe pain and discomfort imaginable'.

    Time frame: week 1, 2, 3, 4, 5, 6, 7, 8, 9, 14, 27

  3. Visual analogue scale (VAS) of leg radiating pain

    Visual analogue scale of radiating leg pain, minimum 0 to maximum 100,which is a higher score means a worse outcome.

    Time frame: week 1, 2, 3, 4, 5, 6, 7, 8, 9, 14, 27

  4. Visual analogue scale (VAS) of low-back pain

    Visual analogue scale of radiating leg pain, minimum 0 to maximum 100,which is a higher score means a worse outcome.

    Time frame: week 1, 2, 3, 4, 5, 6, 7, 8, 9, 14, 27

  5. Oswestry Disability Index (ODI)

    ODI is a functional disability questionnaire. The possible range of eachitem score is 0 to 5. Total score range is 0 (better outcome) to 100 (worse outcome)

    Time frame: week 1, 5, 9, 14, 27

  6. Fear-Avoidance Beliefs Questionnaire (FABQ)

    FABQ is one of pateint-reported outcome questionnaire which consists of total 16 questions. Through FABQ, the investigator can evaluate fear avoidance responses, especially in physical and occupational activity domain for patients with low-back pain

    Time frame: week 1, 9, 14, 27

  7. Patient Global Impression of Change (PGIC)

    Participants rate the improvement after treatment on a 7-point Likert scale(1, very much improved; 2, much improved; 3, minimally improved; 4, nochange; 5, minimally worse; 6, much worse; or 7, very much worse.)

    Time frame: week 9, 14, 27

  8. Short Form-12 Health Survey version 2 (SF-12 v2)

    The SF-12 consists of 12 questions across 8 domains, and higher scores indicate better health-related quality of life.

    Time frame: week 1, 5, 9, 14, 27

  9. EuroQol-5 Dimension (EQ-5D-5L)

    The EQ-5D-5L consists of 5 questions (mobility, self-care, usual activities, pain, anxiety/depression) that ask about the current state of health, and answers each question with 5 likert. (1=I have no problems about, 2=I have slight problems about, 3=I have moderate problems about, 4=I have severe problems about, 5=I am unable to about)

    Time frame: week 1, 5, 9, 14, 27

07

Study locations

1 site
  • Jaseng Hospital of Korean Medicine
    Seoul, 06110, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Jun 2022, 11 months.

Of 205 non-industry interventional studies with no phase under Radiculopathy, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 30. This study's 11 months is close to that.

Counting every sponsor, half of 217 studies reached it within 12 months; a quarter within 5 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2021
First posted
Apr 6, 2021
StartActual
Jul 9, 2021
Primary completionActual
Jun 28, 2022
CompletionActual
Jun 28, 2022
Last update
Sep 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04833270
Lead sponsor
Jaseng Hospital of Korean Medicine
Collaborators
Korea Institute of Oriental Medicine
Responsible party
Kyoung Sun Park (Chief, Clinical study center, Jaseng Hospital of Korean Medicine) — Principal investigator
First posted
Apr 6, 2021
Start date
Jul 9, 2021
Primary completion
Jun 28, 2022
Completion
Jun 28, 2022
Last update
Sep 27, 2022

Study contacts

Kyoung Sun Park, KMD,Ph.D
principal investigator · Jaseng Hospital of Korean Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion